Parallel
Session
Saturday – April 25
09:45-11:15
Room:
TBC

Session Leads

Steve Jones

Action for Pulmonary Fibrosis Representative

Mechanism of action of fibrosis and new insights on antifibrotic drugs

The anti-fibrotic approach is moving fast in the last years. The improvement in the knowledge of pathogenic mechanisms involved in pulmonary fibrosis has been crucial in advancing in treatment targeting. The more we know the better we treat. The advance in treatment options for any disease requires the patient perspective to better argument the choices and identify urgent needs or improvements that should be deeper analyzed or investigated. The patient centered approach also includes the patient voice and thoughts related to his/her own current and future treatment. Therefore, the objectives of this session is threefold: 1) To overview the main pro-fibrotic pathways implicated in lung fibrosis development and progression; 2) To better understand why the current and new anti-fibrotic medications can inhibit the disease progression and 3) To advance potential future anti-fibrotic combinations.

Key Topics

  • Genetic and genomic predisposition
  • Can we reduce the probability of disease development or progression?
  • What does pro-fibrotic pathway mean?
  • What is the perspective for patient treatment?
  • How the patient will be involved in treatment decisions?

Session Format

A sequence of presentations followed by a debate with the audience.

Speakers

Announced Soon

 Please note that the programme is still updated on a regular basis until finalised.